Lannett works with China partner on insulin generic
Lannett Co. plans to co-develop a generic insulin pharmaceutical product for the U.S. market with YiChang HEC ChangJiang Pharmaceutical Co. Ltd., its strategic partner in China. Lannett said Friday that holds the exclusive U.S.